Immunogenicity and safety of a new hexavalent rotavirus vaccine in Chinese infants: A randomized, double-blind, placebo-controlled phase 2 clinical trial-Reference-Cited by-同舟云学术

Immunogenicity and safety of a new hexavalent rotavirus vaccine in Chinese infants: A randomized, double-blind, placebo-controlled phase 2 clinical trial

Published:2023-08 Issue:2 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Wu Zhi-Wei¹,Jin Fei¹,Li Qing-Liang²,Gao Jia-Mei³,Zhou Hai-Song⁴,Duan Kai²,Gao Zhao¹,Liu Yan³,Hao Zhi-Yong⁴,Chen Wei²,Liu Yue-Yue³,Xu Ge-Lin²,Yang Biao²,Dong Ben²,Zhang Jiu-Wei²,Zhao Yu-Liang¹,Yang Xiao-Ming²

Affiliation:

1. Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People’s Republic of China

2. National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, People’s Republic of China

3. National Institutes for Food and Drug Control, Beijing, China

4. Zhengding County Center for Disease Control and Prevention, Zhengding, People’s Republic of China

Funder

Wuhan Institute of Biological Products Co., Ltd., Hubei, China

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2263228

Reference36 articles.

1. Current Update on Rotavirus in-Silico Multiepitope Vaccine Design

2. Impact of rotavirus vaccine introduction in Abidjan, Côte d’Ivoire

3. Changing Parental Attitudes Towards Rotavirus Vaccine

4. Rotavirus vaccine clinical trials: a cross-sectional analysis of clinical trials registries

5. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis